期刊文献+

烟酸缓释胶囊(锐旨)升高家兔高密度脂蛋白实验研究

Effect of Modified Release Capsule of Nicotinic Acid on Raising High Density Lipoprotein in Rabbits:Experimental Study
下载PDF
导出
摘要 目的:观察烟酸缓释胶囊(锐旨)升高家兔高密度脂蛋白胆固醇(HDL-C)及其对动脉粥样硬化斑块的影响。方法:健康日本大耳白兔26只实验前适应性饲养2周,稳定后随即分组法分为:空白对照组8只,高脂模型组18只。其中空白对照组用普通兔饲料喂养22周;高脂模型组用高脂饲料(每kg普通兔饲料加1%胆固醇+8%熟猪油)喂养。10周后从高脂模型组中随即抽取2只处死。观察动脉斑块形成状况,以确定造模是否成功。造模成功后高脂模型组随机分组,分为高脂对照组、药物治疗组,每组8只。高脂对照组和药物治疗组均改为普通饲料,药物以灌胃法喂食。药物治疗组加用烟酸缓释胶囊0.05g(Kg.d-1),喂饲12周。用药前及用药12周后分别测血清总胆固醇(TC)、甘油三酯(TG)、HDL-C、及低密度脂蛋白胆固醇(LDL-C)。用药后门冬氨酸氨基转移酶(AST)测定,观察主动脉组织病理变化。结果:药物治疗组与高脂对照组相比较,TC、TG、LDL-C降低,HDL-C明显升高,差异有统计学意义(P<0.01)。药物治疗组与高脂对照组之间AST无统计学差异(P>0.05)。镜下观察见药物治疗组内膜增厚明显减轻,斑块内脂质和泡沫细胞数量减少,动脉粥样硬化斑块回缩;斑块面积/内膜面积比值、内膜厚度/中膜厚度比值,内膜厚度均明显降低,差异有统计学意义(P<0.01)。结论:烟酸缓释胶囊(锐旨)能够明显升高血清HDL-C,降低TC、TG、LDL-C;并阻止动脉粥样硬化进展,能使动脉粥样硬化斑块回缩,增厚的内膜变薄;并且其不良反应较少,安全性较高。 OBJECTIVE:To observe the effect of the modified release capsule of Nicotinic Acid on raising high density lipoprotein (HDL-C) and on arteriosclerosis plaque. METHODS:26 Japanese white rabbits were fed on normal diets for 2 weeks prior to experiment and then they were randomly divided into normal control group (n = 8) and high serum lipid model group (n = 18). The normal control group (n = 8) was fed on normal diets for 22 weeks,and the high serum lipid model group (n = 18) was fed on high cholesterol diets (1% cholesterol and 8 % lard stearin were added in every 1 000 g normal diets). 10 weeks later, 2 rabbits were randomly selected and sacrificed to observe the formation of arteriosclerosis plaques so as to make sure whether the modeling was successful or not. After successful modeling, the high serum lipid model group was randomly divided into high serum lipid control group (n = 8) and drug-intervention group (n = 8),with both group fed with normal diets, while the drug-intervention group received additional modified release capsule of Nicotinic Acid (0.05 g· kg^-1 · d^-1 , ig) for 12 weeks. Serum levels of TC, TG, HDL-C and LDL-C were measured before treatment and at 12 weeks after treatment and AST were measured. The histopathologic change of the aorta was observed after treatment. RESULTS : In Nicotinic Acid group compared with high serum lipid control group, serum levels of TC, TG and LDL-C were lower while the level of HDL-C was significantly higher, showing significant differences between the two groups (P 〈 0.01 ). However, there was no significant difference between the two groups in AST level ( P 〉 0.05). Under microscope, the thickening of intima was significantly lessened, the lipid within the plaque, the number of foam cells, the atheromatous area, the plaques area / intima area ratio and the intima thickness /media thickness ratio as well as the intima thickness were all significantly decreased in Nicotinic Acid group compared with high serum lipid control group,showing significant differences between the two groups (P 〈 0.01 ). CONCLUSION:Modified release capsule of Nicotinic Acid could obviously increase serum HDL-C, decrease serum levels of TC, TG and LDL-C. Meanwhile, it could inhibit the progression of atherosclerosis, decrease the atheromatous area and reduce the thickness of the thickened intima yet with mild side effect but good safety.
出处 《中国医院用药评价与分析》 2008年第12期925-929,共5页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 烟酸缓释胶囊 血脂 高密度脂蛋白 动脉粥样硬化 Modified release capsule of Nicotinic Acid Serum lipid High density lipoprotein Atherosclerosis
  • 相关文献

参考文献25

  • 1Libby P, Aikawa M, Schonbeck U. Cholesterol and atherosclerosis[ J ]. Biachim Biophy Acta, 2000, 1529 ( 1-3 ) : 299.
  • 2Gotto A M, Whitney E, Stein E A, et al. Relationship between baseline and on - treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronarya Atherosclerosis Prevention Study ( AFCAPS/Tex CAPS) [ J ] . Circulation, 2000, 101 (5) : 477.
  • 3Brewer HB Jr. Increasing HDL Cholesterol Levels[J] . N Eng J Med,2004,350(15) :1 491.
  • 4Li X, Chyu KY, Faria Neto JR, et al. Differential Effects of Apolipoprotein A - I - mimetic peptide on evolving and established atherosclerosis in apolipoprotein E- null mice[J]. Circulation ,2004,110(12) : 1 701.
  • 5Michae IM. Niacin as acomponent of combination therapy for dyslipidemia [ J ]. Mayo Clin Proc, 2003,78 (6) : 735.
  • 6Ganji SH Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease (review)[ J]. J Nutr Biolchem, 2003,14(6) :298.
  • 7赵秀丽,胡大一,贾三庆,华琦,柯元南,郝玉明,朱建华,曹克将,张廷杰,何作云,李燕芳,廉哲勋,马虹.烟酸缓释片治疗血脂异常的临床疗效和安全性的多中心临床研究[J].中国综合临床,2006,22(3):198-199. 被引量:8
  • 8Kajinami K,Takekeshi N. Cholesterol absorption inhibitors in development as potential therapeutics[ J]. Expert Opin lnvestig Drugs ,2002,11 (6) :831.
  • 9Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low - density lipoprotein size to progression of coronary artery disease in the Pravastain Limitation of Atherosclerosis in the Coronary Arteries(PLAC - Ⅰ) trial[J]. AM J Cardiol,2002,90( 2 ) :89.
  • 10方微 张慧信 王绿娅.粘附分子、炎症与动脉粥样硬化.中国动脉硬化杂志,2002,10(39):64-64.

二级参考文献22

  • 1Michael M.Niacin as a component of combination therapy for dyslipidemia[J].Mayo Clin Proc,2003,78(6):735-742.
  • 2Knopp RH,Alagona P,Davidson M,et al.Equivalent efficy of a time-release form of niacin(niaspan) given once-night versus plain niacin in the management of hyperlipidemia[J].Metabolism,1998,47(9):1097-1104.
  • 3Guyton tohn R,Blazing Michael A,Tames H,et al.Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol[J].Arch Intern Med,2000,160(8):1177-1184.
  • 4Von Joanne T,Pan Jianqiu,Talat W,et al.Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes[J].Am J Cardiol,2002,89(11):1306-1308.
  • 5Yerneni K K,Diabetes,1999年,48卷,855页
  • 6Sen R,Cell,1986年,46卷,705页
  • 7Barter P, Kastelein J, Nunn A ,et al. High density lipoprotein(HDLs)and atherosclerosis; the unanswered questions [J]. Atherosclerosis,2003,168:195-211.
  • 8Barter P J. HDL and reverse cholesterol transport [J]. Curr Opin Lipidol, 1993 ;4:210-217.
  • 9Fielding C J, Fielding P E. Molecular physiology of reverse cholesterol transport [J]. J Lipid Res, 1995 ;36: 211-228.
  • 10Krause B R, Auerbach B J. Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis [J].Curr Opin Investig Drugs. 2001,2 (3) :375-381.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部